· Web viewCurrently she is focusing on Alzheimer’s disease (AD) progression due to...

2

Click here to load reader

Transcript of · Web viewCurrently she is focusing on Alzheimer’s disease (AD) progression due to...

Page 1: · Web viewCurrently she is focusing on Alzheimer’s disease (AD) progression due to irregular processing of amyloid precursor protein (APP) by β-secretases and -secretases into

Sneham Tiwari (MS)Graduate StudentCenter for Personalized Nanomedicine Institute of NeuroImmune Pharmacology Email: [email protected] , Tel | 305.348.1490

Ms. Tiwari is currently 3rd year graduate student in Biomedical sciences under Prof. Madhavan Nair, at the Centre of Personalized Nanomedicine, Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA. She completed her masters in Applied Microbiology from Vellore Institute of Technology, India. She has research experience as a Project fellow in Council of Scientific & Industrial Research- Centre for Cellular and Molecular Biology, India. She has been working in the field of understanding molecular aspects of HIV and NeuroAIDS, differences between HIV-1 clade B and Clade C and exacerbating effects of drugs of abuse on HIV infected patients. Currently she is focusing on Alzheimer’s disease (AD) progression due to irregular processing of amyloid precursor protein (APP) by β-secretases and -secretases into Aβ40 (Beta amyloid 40) and Aβ42 (Beta amyloid 42), leading to aggregation and plaque formation contributing to AD. She is studying the neutralizing effect of purified components of natural therapeutic compounds, on toxic effects Aβ amyloid plaques. She is exploring the application of magnetoliposomes in efficient transmigration of therapeutic drugs across blood brain barrier models, increasing the bioavailability as well as efficiency of drugs in CNS.

Her main research focus are: Dose optimization and neutralizing effect of drug against abnormal accumulation of Aβ

in Alzheimer’s disease, in-vitro. Development of nanoformulation for efficient transmigration against blood brain

barrier and effect on Aβ toxicity in neuronal cell lines. Characterization of loading, release, and in vitro efficacy evaluation of developed

nanoformulation. Neurobehavioral studies with AD mouse models and effects of anti-Alzheimer’s drugs.

Selected Publication 1. Kaushik A, Jayant RD, Tiwari S, Vashist A, Nair M. “Nano-biosensors to detect beta-

amyloid for Alzheimer's disease management.” Biosensors and Bioelectronics 80, 273-287 (2016).

2. Kaushik A, Tiwari S, Jayant RD, Marty A, Nair M. “Towards detection and diagnosis of Ebola virus disease at point-of-care.” Biosensors and Bioelectronics 75, 254-72. (2015).

3. Kaushik A, Shah P, Vabbina PK, Jayant RD, Tiwari S, Vashist A, Yndart A, Nair M. “A label-free electrochemical immunosensor for beta-amyloid detection.” Analytical Methods 8, 6115-6120 (2016).

4. Tiwari S, Nair MP, Saxena SK. Latest trends in drugs of abuse – HIV infection and neuroAIDS. Future Virology. 8, 121–127 (2013).

Page 2: · Web viewCurrently she is focusing on Alzheimer’s disease (AD) progression due to irregular processing of amyloid precursor protein (APP) by β-secretases and -secretases into

5. Saxena SK, Tiwari S, Nair MP. “A Global Perspective on HIV/AIDS”. Science. 337, 798 (2012).

Personal Web links: 1. https://scholar.google.com/citations?user=TXqF7pMAAAAJ&hl=en 2. http://www.medicine.fiu.edu/education/phd/phd-students/index.html